France's biosimilars market size was valued at $0.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 21.4% from 2022 to 2030 and will reach $2.4 Bn in 2030. The market is segmented by product type and indication type. The France Biosimilars market will grow with the increased incidence of chronic illnesses, rising healthcare expenses, and the demand for affordable biologic medicine substitutes. To get a detailed report, contact us at - info@insights10.com
2. This report presents a strategic analysis of the France Biosimilars
Market and a forecast for its development in the medium and long
term. It provides a comprehensive overview of the market value,
dynamics, segmentation, main players, growth and demand drivers,
challenges & future outlook, etc. This is one of the most comprehensive
reports about the France Biosimilars Market, and offers unmatched
value, accuracy, and expert insights.
3. 3
A Sample Report on France Biosimilars Market Analysis I Confidential
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology
Report Scope
4. 4
A Sample Report on France Biosimilars Market Analysis I Confidential
CONTENT PG. NO.
1. Biosimilars Market Overview 07-13
1.1. Overview
1.2. France Overview
1.3. Economic Overview: France
1.4. Biosimilars Market in France
1.5. Biosimilars Scenario in France
2. Market Size and Forecasting 14-19
2.1. Market size and forecasts (Excel and Methodology)
2.2. Market Segmentation
2.2.1. By Indication
2.2.2. By Distribution Channel
2.2.3. By Route of Administration
Table of Content
5. 5
A Sample Report on France Biosimilars Market Analysis I Confidential
CONTENT PG. NO.
3. Market Dynamics 20-24
3.1. Market Growth Drivers
3.2. Market Restraints
4. Competitive Landscape 25-34
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Pfizer
4.2.2. Celltrion
4.2.3. Amgen
4.2.4. Sandoz
4.2.5. Mylan
4.2.6. Teva
Table of Content
6. 6
A Sample Report on France Biosimilars Market Analysis I Confidential
CONTENT PG. NO.
4.2.7. Samsung Bioepis
4.2.8. Biogen
4.2.9. Fresenius Kabi
4.2.10. Merck
5. Pricing & Reimbursement 35-39
5.1. Reimbursement Regulation in France
5.2. Reimbursement Process
6. Methodology & Scope 40-71
Table of Content
8. 1.1 Biosimilars Overview
▪ Biosimilars are biological medications that are highly similar to an FDA-approved biologic currently
on the market, known as a reference product and differ in no clinically significant ways
▪ Biosimilars mimic the reference product's structure, biological activity, effectiveness, safety, and
immunogenicity profile as closely as possible
▪ Process of developing and approving biosimilars is more stringent than that of generic
medications as they are manufactured using living cells
Here are some common types of biosimilars based on their biological composition:
Type Application Use
Monoclonal Antibody
Biosimilars
Aids the body’s immune system to fight
infections
Cancer, autoimmune diseases, etc
Peptide and Protein
Biosimilars
Play an important role in multiple
functions of the body
Diabetes, Anemia, etc
G-CSF Biosimilars Stimulates the production of WBCs Neutropenia
EPO Biosimilars Stimulates the production of RBCs Anemia
9. 9
A Sample Report on France Biosimilars Market Analysis I Confidential
France Market
~$xx Bn Market
➢ Africa: $ __
➢ APAC: $ __
➢ Europe: $ __
➢ LATAM: $ __
➢ North America: $ __
Regional Analysis
Illustrative
1.1 Biosimilars Scenario in the World
10. 10
A Sample Report on France Biosimilars Market Analysis I Confidential
▪ Please be aware that this sample report is
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
▪ In this section you will get an understanding
of the demographics of the country/region,
which includes the population, GDP,
healthcare expenditure and other details
related to the topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information related
to the topic or subject matter of interest
Illustrative
64.79 Mn
Population of France in
2023
$2,782.9 Bn
Is the Gross Domestic
Product in France in 2022
42 years
Is the median age in France
$ 4,769
Health expenditure per
person in France in 2022
1.2 France Overview
11. 11
A Sample Report on France Biosimilars Market Analysis I Confidential
1.3 Economic Overview: France
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of France, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of France, (2020-2030)
Population Split (2023)
Male
49%
Female
51%
By Gender By Age Group
0-14
15-24
25-54
55-64
65+
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative
12. 12
A Sample Report on France Biosimilars Market Analysis I Confidential
▪ Please be aware that this sample report is
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
▪ In this section you will get an understanding
of the topic, which includes the prevalence of
the disease, the application of medical
devices, new technology, and other details
related to the topic in France
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information related
to the topic or subject matter of interest
Illustrative
80%
Market Penetration of Biosimilars
in a hospital setting in France in
2021
3%
Market Share of
Biosimilars of the total
Pharmaceutical Market in
France
80%
Market Penetration Target for
Biosimilars in France by 2025
48%
Market Share of Biosimilars
of the total Biological
Market in France
1.4 Statistics at a Glance: Biosimilars Market in France
13. 13
A Sample Report on France Biosimilars Market Analysis I Confidential
1.5 Biosimilars Scenario in France
Illustrative
➢ Prescribing and Use: In order to save healthcare costs, medical practitioners in France are urged to prescribe biosimilars in place of
reference biologic products
➢ Regulation and Approval: The European Medicines Agency (EMA) oversees biosimilars in France on the European level. A biosimilar
may be sold in France after receiving European approval
➢ Market Share: As healthcare providers and institutions use biosimilars to reduce treatment costs, the market share of biosimilars in France
has been rising, especially for biologics that are often prescribed
➢ Education and Awareness: Efforts to enlighten patients, healthcare providers, and the general public about biosimilars are still underway
in France
➢ Reimbursement: Particular reimbursement guidelines are in place in the public and private sectors of the French healthcare system to
promote the use of biosimilars and keep costs under control
➢ Challenges: Some patients and healthcare professionals may continue to have concerns regarding switching from reference biologics to
biosimilars because of concerns about efficacy differences, interchangeability, and trust
15. 15
A Sample Report on France Biosimilars Market Analysis I Confidential
▪ Please be aware that this sample report is
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
▪ In this section you will get an understanding
of the overall market, which includes the
market size, current trends and other details
related to the topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information related
to the topic or subject matter of interest
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
France Biosimilars Market Forecast, 2022-2030
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
($Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
France Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
France Market Size ($Bn) 61 74 84 87 91 95 99 106
Illustrative
2.1 Market size and forecasts (Excel and Methodology)
16. 16
A Sample Report on France Biosimilars Market Analysis I Confidential
▪ In this section you will get an understanding of the segmentations which will cover the France Biosimilars Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Indication
Oncology
Autoimmune Diseases
Hematology
Endocrinology
Infectious Diseases
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Direct-to-Patient Pharmacies
Online Pharmacies
Route of Administration
Intravenous
Subcutaneous
Topical
Others
Illustrative
2.2 Snapshot of Biosimilars Market Segmentation
17. 17
A Sample Report on France Biosimilars Market Analysis I Confidential
France Biosimilars Market Share, By Indication
(2022)
▪ Oncology is the largest segment for
biosimilars in France and it had a market
value of more than 40% in 2021
▪ Use of biosimilars for Oncology is growing
rapidly due to factors the high prevalence
of cancer and the availability of a large
number of biosimilars for cancer treatment
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic
Illustrative
2.2.1 Market Segmentation: By Indication
Oncology
Autoimmune
Diseases
Hematology
Endocrinology
Infectious
Diseases
Others
18. 18
A Sample Report on France Biosimilars Market Analysis I Confidential
France Biosimilars Market Share, By Distribution Channel
(2022)
Hospital
Pharmacies
Retail
Pharmacies
Direct-to-Patient
Pharmacies
Online Pharmacies
▪ Most commonly used distribution channel
for biosimilars is hospital pharmacies, as
biosimilars are usually administered in
hospitals making it convenient for patients
to procure them from the hospital
pharmacy
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Illustrative
2.2.2 Market Segmentation: By Distribution Channel
19. 19
A Sample Report on France Biosimilars Market Analysis I Confidential
France Biosimilars Market Share, By Route of Administration
(2022)
▪ Intravenous biosimilars account for the
largest share of the biosimilar market in
France
▪ Also, subcutaneous biosimilars are gaining
popularity due to the ease of self-
administration
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic
Illustrative
2.2.3 Market Segmentation: By Route of Administration
Intravenous
Subcutaneous
Topical
Others
21. 21
A Sample Report on France Biosimilars Market Analysis I Confidential
3.1 Market Growth Drivers
3.1.1 Rising prevalence of chronic diseases in France with more than 20 Mn people suffering from at least one
chronic disease
Illustrative
▪ Prevalence of chronic diseases is increasing in France
owing to reasons like an aging population, increased
exposure to environmental risk factors, unhealthy lifestyles,
etc
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
22. 22
A Sample Report on France Biosimilars Market Analysis I Confidential
3.1 Market Growth Drivers (Continued)
▪ Out-of-pocket healthcare spending in France was reported to account for
19.5% of the total healthcare spending
▪ As biosimilars are more affordable compared to reference biologics, it
has started gaining popularity as the preferred treatment option for
patients and payers in France
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
2010 2022 2030
3.1.2 Increasing demand for more affordable treatment options due to rising healthcare costs, with about 14% of the
French population having difficulty in affording healthcare
Illustrative
23. 23
A Sample Report on France Biosimilars Market Analysis I Confidential
3.1 Market Growth Drivers (Continued)
▪ Government in France is extending support for the use of biosimilars
through its numerous initiatives including a reimbursement system
favoring biosimilars over reference biologics and providing financial
support for biosimilar research and development
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
3.1.3 Government initiatives, with the French government setting a target of 80% biosimilar penetration by 2025
Illustrative
24. 24
A Sample Report on France Biosimilars Market Analysis I Confidential
3.2.1 Competition from
alternative products like
reference biologics
▪ Only 15% of rural doctors in
France expressed willingness to
prescribe biosimilars over
reference biologics
▪ Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪ In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
3.2.2 Complex regulatory
process for biosimilars in
France
▪ Average approval time for a
biosimilar in France is 27
months, which delays the
launch of new biosimilars
▪ Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪ In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
3.2.3 Lack of awareness of
biosimilars
▪ Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪ In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
▪ Final report will be
comprehensive and detailed, and
it will include data, analysis,
trends, and other relevant
information related to the topic
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative
3.2 Market Restraints
26. 26
A Sample Report on France Biosimilars Market Analysis I Confidential
Company 1
Company 2
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10
Revenue of Major players in the France Biosimilars
Market ($ Mn) ▪ Please be aware that this sample report is
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information related
to the topic or subject matter of interest
Illustrative
4.1 Major Market Share
27. 27
A Sample Report on France Biosimilars Market Analysis I Confidential
Key Note:
Pfizer
1 Teva
6
Celltrion
2 Samsung Bioepis
7
Amgen
3 Biogen
8
Sandoz
4 Fresenius Kabi
9
Mylan
5 Merck
10
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials (As per availability)
▪ If there are specific companies that you
would like to be included in the report, please
let us know via email
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
4.2 Key Players in France Biosimilars Market
Illustrative
28. 28
A Sample Report on France Biosimilars Market Analysis I Confidential
4.2.1 Pfizer
Founded in: 1849
HQ: New York, USA
Type: Private
Revenue: $100.3 Bn (global)
Website: www.pfizer.com
▪ Pfizer is a leading global pharmaceutical company which is one of
the dominant player in the French biosimilars industry
▪ It is committed to developing and commercializing premium
biosimilars that are safe, effective as well as affordable
▪ It is investing significantly in the development of novel biosimilars
with over 20 of them in development across a variety of
therapeutic categories
Solutions offered
➢ Diagnostics
➢ Biologics and Biosimilars
➢ Pharmaceuticals
➢ Veterinary products
Some of the Biosimilars offered by Pfizer
Inflectra (Infliximab) Treatment of Crohn’s disease,
etc
Trazimera (Trastuzumab) Treatment of Breast and
Stomach Cancer
Rixathon (Rituximab) Treatment of Rheumatoid
arthritis
Zirabev (Bevacizumab) Treatment of Cancer
Oct 2023: Pfizer has recently received FDA approval for its
biosimilar ABRILADA™, which is one of only two biosimilars that
are interchangeable with Humira®
Oct 2023: Pfizer announced positive topline data for their mRNA-
based combination vaccine program against influenza and
COVID-19
Oct 2023: Pfizer France Head Reda Guiha was questioned by
the Senate's committee of enquiry into drug shortages
Illustrative
Recent Activity / Press Coverage
29. 29
A Sample Report on France Biosimilars Market Analysis I Confidential
4.2.1 Pfizer (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Seagen Inc.
Acquisition $43 Bn Mar, 2023
▪ Pfizer announced that it would acquire Seagen, a global
biotechnology company that discovers, develops, and
commercializes transformative cancer medicines
▪ This acquisition is expected to enhance Pfizer's position the
segment of Oncology, with Seagen's medicines, late-stage
development programs, and pioneering expertise in Antibody-
Drug Conjugates (ADCs) strongly complementing Pfizer's
Oncology portfolio
Arena
Pharmaceuticals
Acquisition $6.7 Bn Mar, 2022
▪ Pfizer acquired Arena Pharmaceuticals, a clinical-stage startup
creating novel potential treatments for the treatment of various
immuno-inflammatory illnesses
▪ This acquisition granted Pfizer access to Arena's portfolio of
potential treatments for the fields of gastrointestinal, dermatology,
and cardiology
Latest Deals - Mergers and Acquisitions
Illustrative
30. 30
A Sample Report on France Biosimilars Market Analysis I Confidential
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
4.2.1 Pfizer (continued)
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative
31. 31
A Sample Report on France Biosimilars Market Analysis I Confidential
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Biosimilars
Products
Recent Activity / Press Coverage
32. 32
A Sample Report on France Biosimilars Market Analysis I Confidential
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
33. 33
A Sample Report on France Biosimilars Market Analysis I Confidential
4.2.2 Company 2 (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
34. 34
A Sample Report on France Biosimilars Market Analysis I Confidential
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
4.2.2 Company 2 (continued)
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
36. 36
A Sample Report on France Biosimilars Market Analysis I Confidential
5.1 Reimbursement Regulation for Biosimilars in France
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
Public healthcare coverage is provided by the government and includes
various programs
▪ Shift towards value-based care has been a significant trend in France healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative
37. 37
A Sample Report on France Biosimilars Market Analysis I Confidential
5.2 Reimbursement Process
The reimbursement process in France healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative
38. 38
A Sample Report on France Biosimilars Market Analysis I Confidential
5.2 Reimbursement Process (Continued)
The reimbursement process in France healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
MoH
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative
41. Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Life-sciences Market
Research Reports you
can trust
www.insights10.com
42. A large database of over 30,000 syndicated
market research reports in pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions
www.insights10.com
43. Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life-sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com
44. Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com
50. Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life-sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions
51. Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis
52. Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players
53. What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read
55. Research Methodology
▪ Insights10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US Dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)
56. Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research
57. Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary
58. Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2021 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors
59. 2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Market Size & Revenue Forecast,
Market Segmentation, Growth drivers and restraints,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (4 to 7 working days) with
purchase. We will provide you with data that is
currently not a part of our scope as a part of
customization
Avail customized purchase options to meet your
exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period
61. “The business decision-making process is no longer as straightforward
as it used to be. It requires insights generated at the right time, based
on reliable data interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market research and are
committed to providing our clients with the right intelligence and
insights to make business decisions quickly and efficiently.
Insights10 is a unique platform that combines deep domain expertise,
nuanced data at a country and functional area level, and years of
experience working with some of the best organizations in the world,
generating insights that provides substantial competitive advantage.”
Dr. Purav Gandhi
Founder & CEO
Click to watch the YouTube
Video
CEO Speaks
62. Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
68. What our clients say
I've had the pleasure of availing Insights10’s services several times, and I've
always been impressed by their expertise, professionalism, and dedication to
providing us with the highest quality data and insights. Whether one is looking to
launch a new product, expand into a new market, or better understand one's target
customers, Insights10 insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and
they use their knowledge to develop customized research solutions that meet the
specific needs of each client. I highly recommend Insights10 to anyone looking for
a reliable and experienced partner in healthcare market research. They're a
valuable asset to any company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
69. Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis.
The quality of the report was excellent, and you managed to complete it in record
time. I was also impressed by your quick turnaround on the topics discussed as a
follow up after the report's first version; you managed to gather the information
required, plus a very good analysis.
I will definitely consider working with you again if the opportunity arises, and will
not hesitate in recommending you to colleagues working in the field Thank you
again for your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID
What our clients say
70. Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health, London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.
What our clients say